Home LiteratureArticle Details
PMID: 20485677 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

PloS one ·Vol. 5 ·No. 5 ·2010-05-12 ·Pages e10471

Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E, Kast WM

Abstract

Sperm protein (Sp17) is an attractive target for ovarian cancer (OC) vaccines because of its over-expression in primary as well as in metastatic lesions, at all stages of the disease. Our studies suggest that a Sp17-based vaccine can induce an enduring defense against OC development in C57BL/6 mice with ID8 cells, following prophylactic and therapeutic treatments. This is the first time that a mouse counterpart of a cancer testis antigen (Sp17) was shown to be expressed in an OC mouse model, and that vaccination against this antigen significantly controlled tumor growth. Our study shows that the CpG-adjuvated Sp17 vaccine overcomes the issue of immunologic tolerance, the major barrier to the development of effective immunotherapy for OC. Furthermore, this study provides a better understanding of OC biology by showing that Th-17 cells activation and contemporary immunosuppressive T-reg cells inhibition is required for vaccine efficacy. Taken together, these results indicate that prophylactic and therapeutic vaccinations can induce long-standing protection against OC and delay tumor growth, suggesting that this strategy may provide additional treatments of human OC and the prevention of disease onset in women with a family history of OC.

MeSH Terms
Animals Antigens, Neoplasm/immunology Cancer Vaccines/immunology Cell Line Cytotoxicity, Immunologic/immunology Disease Models, Animal Female Humans Injections, Intraperitoneal Interferon-gamma/blood Major Histocompatibility Complex/immunology Mice Mice, Inbred C57BL Ovarian Neoplasms/blood,immunology,pathology,prevention & control Survival Analysis T-Lymphocytes, Cytotoxic/immunology T-Lymphocytes, Helper-Inducer/immunology T-Lymphocytes, Regulatory/immunology Time Factors Tumor Necrosis Factor-alpha/blood Vaccination
Chemicals
Antigens, Neoplasm Cancer Vaccines Tumor Necrosis Factor-alpha Interferon-gamma
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Chiriva-Internati Maurizio
Division of Hematology and Oncology, Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America. [email protected]
Yu Yuefei
Mirandola Leonardo
Jenkins Marjorie R
Chapman Caroline
Cannon Martin
Cobos Everardo
Kast W Martin
References (59)
59 references, click to expand
  1. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.
    J Immunol Methods. 2007 Apr 10;321(1-2):86-93 PMID: 17336323
  2. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Anticancer Res. 2009 Aug;29(8):2875-84 PMID: 19661290
  3. Characterization of the rabbit sperm membrane autoantigen, RSA, as a lectin-like zona binding protein.
    Dev Biol. 1988 Sep;129(1):231-40 PMID: 3410159
  4. Cellular immunotherapy for ovarian cancer.
    Expert Opin Biol Ther. 2009 Jun;9(6):677-88 PMID: 19456205
  5. Sperm protein 17 is expressed in human somatic ciliated epithelia.
    J Histochem Cytochem. 2004 Apr;52(4):549-54 PMID: 15034007
  6. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.
    Blood. 2009 Aug 6;114(6):1141-9 PMID: 19470694
  7. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.
    Blood. 2003 Nov 1;102(9):3100-7 PMID: 12855576
  8. The immunogenicity of CpG-antigen conjugates.
    Adv Drug Deliv Rev. 2009 Mar 28;61(3):243-7 PMID: 19174176
  9. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome.
    Nature. 2008 Apr 10;452(7188):773-6 PMID: 18337720
  10. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells.
    J Exp Med. 1993 Sep 1;178(3):1041-8 PMID: 8102388
  11. The cancer/testis genes: review, standardization, and commentary.
    Cancer Immun. 2004 Jan 23;4:1 PMID: 14738373
  12. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
    Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52 PMID: 17517626
  13. Tumor-specific shared antigenic peptides recognized by human T cells.
    Immunol Rev. 2002 Oct;188:51-64 PMID: 12445281
  14. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.
    Cancer Invest. 2004;22(3):417-34 PMID: 15493363
  15. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    J Natl Cancer Inst. 2002 Dec 4;94(23):1773-9 PMID: 12464649
  16. Characterization of Sp17: a ubiquitous three domain protein that binds heparin.
    Biochem J. 2001 Jul 1;357(Pt 1):25-31 PMID: 11415432
  17. Expression of sperm protein 17 (Sp17) in ovarian cancer.
    Int J Cancer. 2004 Mar 1;108(6):805-11 PMID: 14712480
  18. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.
    Immunol Rev. 2002 Oct;188:22-32 PMID: 12445278
  19. A review of the current evidence for maintenance therapy in ovarian cancer.
    Gynecol Oncol. 2009 Nov;115(2):290-301 PMID: 19717182
  20. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk.
    Eur J Immunol. 2001 Aug;31(8):2277-83 PMID: 11477539
  21. Development of a syngeneic mouse model for events related to ovarian cancer.
    Carcinogenesis. 2000 Apr;21(4):585-91 PMID: 10753190
  22. T-cell proliferation in vivo and the role of cytokines.
    Philos Trans R Soc Lond B Biol Sci. 2000 Mar 29;355(1395):317-22 PMID: 10794049
  23. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.
    J Immunol. 2009 Aug 15;183(4):2475-83 PMID: 19635913
  24. Sperm protein 17 is expressed in human nervous system tumours.
    BMC Cancer. 2006 Jan 26;6:23 PMID: 16438728
  25. T cell-mediated suppression of angiogenesis results in tumor protective immunity.
    Blood. 2005 Sep 15;106(6):2026-32 PMID: 15920006
  26. Precursor lesions of ovarian epithelial malignancy.
    Histopathology. 2001 Feb;38(2):87-95 PMID: 11207821
  27. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer.
    Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10 PMID: 18832156
  28. IL-4 secreted from individual naive CD4+ T cells acts in an autocrine manner to induce Th2 differentiation.
    Eur J Immunol. 2002 May;32(5):1428-33 PMID: 11981831
  29. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7 PMID: 10077623
  30. Human T cell responses against melanoma.
    Annu Rev Immunol. 2006;24:175-208 PMID: 16551247
  31. Adoptive immunotherapy for cancer: building on success.
    Nat Rev Immunol. 2006 May;6(5):383-93 PMID: 16622476
  32. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.
    Science. 2008 Nov 14;322(5904):1097-100 PMID: 19008445
  33. Tumor vaccine for ovarian carcinoma targeting sperm protein 17.
    Cancer. 2002 May 1;94(9):2447-53 PMID: 12015770
  34. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract.
    Nat Med. 2005 May;11(5):531-7 PMID: 15821746
  35. The immunotherapy of patients with ovarian cancer.
    J Immunother. 2002 May-Jun;25(3):189-201 PMID: 12000860
  36. Prophylactic oophorectomy.
    Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):597-609 PMID: 12413937
  37. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  38. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells.
    J Transl Med. 2008 Apr 29;6:21 PMID: 18445282
  39. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma.
    Blood. 2002 Aug 1;100(3):961-5 PMID: 12130509
  40. Cancer statistics, 2005.
    CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 PMID: 15661684
  41. Global cancer statistics, 2002.
    CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 PMID: 15761078
  42. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics?
    Am J Hematol. 2005 Sep;80(1):6-11 PMID: 16138340
  43. Tumor-specific Th17-polarized cells eradicate large established melanoma.
    Blood. 2008 Jul 15;112(2):362-73 PMID: 18354038
  44. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.
    J Clin Invest. 2009 Oct;119(10):3011-23 PMID: 19741298
  45. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.
    J Immunother. 2008 Oct;31(8):693-703 PMID: 18779750
  46. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo.
    J Immunol. 2008 Sep 1;181(5):3137-47 PMID: 18713984
  47. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
    J Exp Med. 2003 Dec 15;198(12):1875-86 PMID: 14676299
  48. Cancer regression in patients after transfer of genetically engineered lymphocytes.
    Science. 2006 Oct 6;314(5796):126-9 PMID: 16946036
  49. Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors.
    Cancer Immunol Immunother. 2008 Dec;57(12):1757-69 PMID: 18351336
  50. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons.
    Springer Semin Immunopathol. 2000;22(1-2):77-84 PMID: 10944802
  51. Th17 cells in ovarian cancer.
    Blood. 2009 Aug 6;114(6):1134-5 PMID: 19661273
  52. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.
    Immunology. 2007 Sep;122(1):15-27 PMID: 17451465
  53. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
    J Transl Med. 2008 Jan 08;6:2 PMID: 18182107
  54. Differential signaling by CpG DNA in DCs and B cells: not just TLR9.
    Trends Immunol. 2003 Oct;24(10):519-22 PMID: 14552833
  55. Hereditary ovarian cancer.
    Crit Rev Oncol Hematol. 2009 Jan;69(1):28-44 PMID: 18656380
  56. Differentiation of effector CD4 T cell populations (*).
    Annu Rev Immunol. 2010;28:445-89 PMID: 20192806
  57. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
    J Immunother. 2009 Feb-Mar;32(2):101-8 PMID: 19238008
  58. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.
    Infect Immun. 2003 Sep;71(9):5121-9 PMID: 12933855
  59. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.
    J Virol. 2005 Feb;79(4):2024-32 PMID: 15681404
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
DOI
10.1371/journal.pone.0010471
Email
[email protected]
Published
2010-05-12
Epub
2010-00-12
Pages
e10471
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC2868870
Subset
IM
External Links
PubMed source DOI: 10.1371/journal.pone.0010471 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2